Used in targeted cancer therapies, particularly for tumors overexpressing EGFR or its mutant form EGFRvIII, such as glioblastoma, non-small cell lung cancer, and head and neck cancers. This antibody serves as a reference for developing diagnostic assays and therapeutic antibodies by specifically binding to the EGFRvIII mutation, which is associated with aggressive tumor behavior and poor prognosis. It enables detection and quantification of EGFRvIII in tissue samples, supporting research into patient stratification and treatment response. Additionally, it can be used as a benchmark in the design of antibody-drug conjugates, biosimilars, and immunotherapies aiming to inhibit EGFR signaling pathways.